I
Immatics biotechnologies
Combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets
At a glance
- Status
- Listed
- Listing
- Public via SPAC 2020
News
Open roles
Immatics biotechnologies in the Tübingen ecosystem
The Immatics biotechnologies office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
- EVEMBL Ventures
- 3G3i Group
- WPWellington Partners
- L-L-Bank
- VCVinci Capital
- GEGrazia Equity
Series B and later11 investors entered at this stage
- BSBristol-Myers Squibb
- DCDH Capital
- MCMIG Capital
b2venture- KFKfW
- DHdievini Hopp Biotech holding
- CECelgene
- SVSwisscom Ventures
- AGAT Impf GmbH
- AMAmgen
- DPDezima Pharma
Source: Dealroom Talent Intelligence.
Alumni founders
Former Immatics biotechnologies employees who went on to found companies, sorted by Dealroom signal score.
Harpreet SinghUnited States
IAIOmx Therapeutics AGEst. 2016
Sebastian Meier-EwertGermany
ATAffinia TherapeuticsEst. 2019
Rob Johnson.United StatesPatents
204 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
See Immatics biotechnologies on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
